Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial, page-45

this and previous announcements allude to “looking to move forward with sponsored back non dilutive studies”
given PTX has some ppl of interest with big time connections and with proven track records in executing highly valuable transactions, it’s almost seems imminent that PTX-200 is being shopped around. With 3 back to back extremely encouraging results, I’d guess that the likelihood of a something happening in this space could be only moments away.
I would love to hear something more concrete on this in the coming days/weeks. It surely must be in consideration. I’d guess the last hurdle stopping this is waiting on readouts for the PTX100 basket study, if there’s encouraging data I’d imagine it’s game on.
IMO the path forward is to partner PTX200, thus enabling PTX to aggressively pursue interests in ptx100.